Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply

Aliment Pharmacol Ther. 2022 Jun;55(12):1590-1591. doi: 10.1111/apt.16966.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cost of Illness
  • Diarrhea
  • Humans
  • Irritable Bowel Syndrome* / epidemiology
  • Prevalence